Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines

AIDS Research and Human Retroviruses

Volumn 18, Issue 9, 2002, Pages 611-618

  Mwau, Matilu ^a   McMichael, Andrew J ^a   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE; VIRUS ANTIGEN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; VALIDATION PROCESS;

AIDS VACCINES; CLINICAL TRIALS; CRYOPRESERVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; PEPTIDES; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 0036431195     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202760019301     Document Type: Article

References (36)

1. Hanke T: Prospect of a prophylactic vaccine for HIV. Br Med Bull 2001;58:205-218.
2. Esparza J and Bhamarapravati N: Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how? Lancet 2000;355:2061-2066.
3. Czerkinsky CC, Tarkowski A, Nilsson LA, Ouchterlony O, Nygren H, and Gretzer C: Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 1984;72:489-496.
4. γ production and evokes local immunological memory. J Clin Invest 1991;88:143-148.
5. + T cells. Int Immunol 1994;6:11-19.
6. + memory T cells. J Exp Med 1997;186:859-865.
7. + T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
8. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, and Schooley RT: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-348.
9. Shepp DH, Daguillard F, Mann D, and Quinnan GV: Human class I MHC-restricted cytotoxic T-lymphocytes specific for human immunodeficiency virus envelope antigens. AIDS 1988;2:113-117.
10. Lieberman J, Fabry JA, Kuo MC, Earl P, Moss B, and Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in gpl60 and reverse transcriptase. J Immunol 1992;148:2738-2747.
11. Tomiyama H, Sakaguchi T, Miwa K, Oka S, Iwamoto A, Kaneko Y, and Takiguchi M: Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Hum Immunol 1999;60:177-186.
12. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, and Weber J: Phase I trial of a MART-1 peptide vaccine with incomplete Freund' s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-2765.
13. γ-ELISPOT assay and chromium-release assay: A four-centre comparative trial. J Immunol Methods 2000;244:81-89.
14. + cytotoxic T lymphocyte response to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis 2000;182:928-932.
15. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611.
16. + responses. J Clin Invest 2001;107:341-349.
17. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder P JR, Walker BD, and HIV Controller Study Collaboration: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001;98:1781-1786.
18. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM, Winkelhake J, and Spack EG: A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997;210:149-166.
19. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, and Walker BD: Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med 2000;192:1819-1832.
20. Hanke T, Schneider J, Gilbert SC, Hill AVS, and McMichael A: DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine 1998;16:426-435.
21. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
22. Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker M, Gilbert SC, Hill AVS, Smith GL, and McMichael A: Immunogenicities of intravenous and intramuscular administrations of MVA-based multi-CTL epitope vaccine for HIV in mice. J Gen Virol 1998;79:83-90.
23. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AVS, Smith GL, and McMichael A: Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
24. Maino VC and Picker LJ: Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression. Cytometry 1998;34:518-525.
25. Wee EG-T, Patel S, McMichael AJ, and Hanke T: A DNA/MVA-based candidate HIV vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 2002;83:75-80.
26. Hanke T and McMichael AJ: Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;6:951-955.
27. Korber TMB, Brander C, Haynes FB, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins DI, eds.: 2000 HIV Molecular Immunology Compendium. Los Alamos National Laboratory, Los Alamos, New Mexico, 2001.
28. γ secreting cells in rhesus macaques. J Immunol Methods 2001;247:49-60.
29. Koch E, Larak M, and Ellendorff F: Comparative studies on in vitro reactivity of fresh and cryopreserved pig lymphocytes. Cryobiology 1991;28:405-412.
30. Reimann KA, Chernoff M, Wilkening CL, Nickerson CE, and Landan AL: Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: Implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol 2000;7:352-359.
31. Weinberg A, Wohl DA, Brown DG, Pott GB, Zhang L, Ray MG, and van der Horst C: Effect of cryopreservation on measurement of cytomegalovirus-specific cellular immune responses in HIV-infected patients. J Acquir Immune Defic Syndr 2000;225:109-114.
32. Lewalle P, Rouas R, Lehmann F, and Martiat P: Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Methods 2000;240:69-78.
33. γ by frozen human peripheral blood mononuclear cells. Cryobiology 1995;32:528-534.
34. Venkataraman M: Effects of cryopreservation on immune responses. X. Decrease in interleukin-12 production by frozen human peripheral blood mononuclear cells is mediated by the endogenously hypersecreted interleukin-10. Cryobiology 1996;33:581-588.
35. γ interferon elispot assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001;8:871-879.
36. Dorrell L, O'Callaghan CA, Britton W, Hambleton S, McMichael A, Smith GL, Rowland-Jones S, and Blanchard TJ: Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro. Vaccine 2000;19:327-336.